Utility of High Flow Nasal Cannula in CO Toxicity

NCT03342209 | Completed

• 1 other identifier: KIA 2016/286
• Study Type: interventional
• Target: 35
• Locations: 1 country
• Sites: 1

Brief Summary

determination of the half-life of COHb in CO-poisoned patients with high flow nasal oxygen therapy in the ED.

Conditions

Carbon Monoxide Poisoning; Environmental Exposure

Keywords

carbon monoxide toxicity; high flow nasal cannula; emergency department

Outcome Measures

Primary Outcomes (1)

• Half life of COHb

  Half life of COHb levels (%) under the high flow nasal oxygen therapy. Elimination rate of COHb will be determined in every 10 minutes according to venous blood gas COHb level.

  between 20 and 120 minutes

Secondary Outcomes (4)

• Adverse Events

  between 0 and 120 minutes

• Device Comfort

  Between 0 and 120 minutes

• Flow Rate Tolerability

  Between 0 and 120 minutes

• Flow Temperature Tolerability

  Between 0 and 120 minutes.

Study Arms (1)

HFNC therapy

EXPERIMENTAL

Fisher\&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.

Device: Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy

Interventions

Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy DEVICE

A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care. The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level. Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes.

HFNC therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patients who are admitted to the emergency department with CO poisoning with a CoHB level of \>10%.
• The patients who accept to participate in the study.

You may not qualify if:

• The patients who are \<18 years old.
• The patients who need mechanical ventilation
• The patients who are implemented oxygen more than 30 minutes before the ED admission
• The patients who will be transferred to the hyperbaric oxygen center before the CoHB levels are decreased to the half.

Sponsors & Collaborators

• Kocaeli University: lead

Study Sites (1)

Kocaeli University Medical Faculty

Kocaeli, Izmit, 41300, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Carbon Monoxide Poisoning; Emergencies

Condition Hierarchy (Ancestors)

Gas Poisoning; Poisoning; Chemically-Induced Disorders; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Elif Yaka, Assoc. Prof.

  Kocaeli University

  STUDY CHAIR

• İbrahim U Özturan

  Kocaeli University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator, MD

Study Record Dates

• First Submitted: October 28, 2017
• First Posted: November 14, 2017
• Study Start: March 1, 2017
• Primary Completion: February 6, 2018
• Study Completion: February 6, 2018
• Last Updated: April 10, 2018

Record last verified: 2017-11

Locations

TU (1)